Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage

Inclusion criteria: 1. Adult patients (at least 20 years old, up to 80 years old) 2. ICH located in the thalamus or basal ganglia. 3. ICH score less than 3 (hematoma volume not greater than 15 ml) and was admitted within 24 hours since onset. 4. The patient or his/her legal representative agrees to join this trial and accept the arrangements of tests within this trial. 5. Patients with normal bone marrow and hematopoiesis (Red blood cell count, white blood cell count, platelet count within reference value). 6. Patients with normal liver function (Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Gamma-glutamyl transferase (γ-GT) within reference value) 7. Patients with normal renal function (Blood urea nitrogen (BUN), creatinine and estimated glomerular filtration rate (eGFR) within reference value) 8. Patients with normal coagulation function (Platelet count, prothrombin time (PT), activate partial thromboplastin time (aPTT), international normalized ratio (INR) within reference value) Exclusion criteria: 1. Image studies conducted after intracerebral incidence and before enrollment showing higher bleeding risks such as spot sign in computed tomography angiography, new intraventricular hemorrhage (IVH), IVH expansion, irregular hematoma border, heterogenous hematoma component or hematoma expansion. 2. Intracerebral hemorrhage located in the cerebral area, below the cerebellar tentorium or ICH score greater than 3 (not including 3). 3. Surgical intevention such as decompressive craniotomy or hematoma evacuation was suggested after evaluation by neurosurgeon. 4. Patients with history of brain trauma, structural brain disease, metabolic brain disease, neuroinflammatory disease or brain neoplasms. 5. Patients that cannot tolerate image studies, including but not limited to those that cannot cooperate, affecting image quality due to agitation, presenting with unstable hemodynamics, installed with pacemakers incompatible with magnetic resonance imaging (MRI), has brain aneurysm clips or clasutorphobic. 6. Patients with medical contraindications to MRI contrast medium, including chronic renal failure (Creatinine clearance rate less than 30ml/min). 7. Patients currently pregnant or expecting pregnancy or breastfeeding in six months. 8. Patients taking oral anti-platelet medication (aspirin, clopidogrel, ticagrelor, cilostzaol) or anti-coagulant (warfarin, dabigatran, rivaroxaban, apixaban, edoxaban) when ICH occurred. 9. Patients with medical contraindications to cilostazol, including heart failure with any severity, any coagulopathy, ventricular tachycardia, ventricular fibrillation, mulitfocal ventricular arrhythmia, severe tachycardic arrhythmia, unstable angina, myocardial infarction within six months, has history of receiving percutaneous coronary intervention, active pathological bleeding and severe hepatorenal insufficiency. 10. Patients with poor blood pressure control (defined as systolic blood pressure greater than 160 mmHg under anti-hypertensive medication). 11. Patients with unstable neurological conditions (defined as increase in National Institute of Health Stroke Scale (NIHSS) greater than 4 or newly occurred conscious change during admission). 12. Patients with life expectancy less than three months. 13. Patients with known allergy to any of the ingredient of the trial medication, and deemed unsuitable for enrollment of the study by the trial host. 14. Patient or legal guardian of the patient refuses to be enrolled within the study.